A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD.
The DOI matches its Crossref record, with a small difference in title or year; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Hallucinogen persisting perception disorder (HPPD) is rarely encountered in clinical settings. It is described as a re-experiencing of some perceptual distortions induced while intoxicated and suggested to subsequently cause functional impairment or anxiety. Two forms exist: Type 1, which are brief "flashbacks," and Type 2 claimed to be chronic, waxing, and waning over months to years. A review of HPPD is presented. In addition, data from a comprehensive survey of 20 subjects reporting Type-2 HPPD-like symptoms are presented and evaluated. Dissociative Symptoms are consistently associated with HPPD. Results of the survey suggest that HPPD is in most cases due to a subtle over-activation of predominantly neural visual pathways that worsens anxiety after ingestion of arousal-altering drugs, including non-hallucinogenic substances. Individual or family histories of anxiety and pre-drug use complaints of tinnitus, eye floaters, and concentration problems may predict vulnerability for HPPD. Future research should take a broader outlook as many perceptual symptoms reported were not first experienced while intoxicated and are partially associated with pre-existing psychiatric comorbidity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Development, reliability, and validity of a dissociation scale
BERNSTEIN, E. M., & PUTNAM, F. W. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198612000-00004 · Cited by 3,793
(2017) · Institute for Social Research eBooks · doi:10.3998/2027.42/139710 · Cited by 1,364
(1993) · Cited by 1,279
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
Strassman, R. J. (1984) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198410000-00001 · Cited by 312
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Hallucinogen persisting perception disorder: what do we know after 50 years?
Halpern, J. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00306-x · Cited by 219
Self-citationThe Psychopharmacology of Hallucinogens
Abraham, H., Aldridge, A. M., & Gogia, P. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00136-2 · Cited by 172
Research works printed but not linked: 6
- Fischer R (1976) On the remembrance of things present: the state-bound and stage-bound nature of consciousness. Man-Environ Syst 6:131–136
- Grinspoon L, Bakalar J (1997) Psychedelics reconsidered, 3rd edn. The Lindesmith Center, New York
- Parish E (1894) Über die Trugwahrnehmungen mit besonderer Berücksichtigung der internationalen Enquete über Wachhalluzinationen bei Gesunden. Schr Ges psychol Forsch 7(8):1–154
- Passie T, Halpern JH (2014) The pharmacology of hallucinogens (Chapter 14). In: Ries RK, Fiellin DA (eds) Principles of addiction medicine, 5th edn. Lippincott Williams & Wilkins, NY
- Substance Abuse and Mental Health Services Administration (SAMHSA) (2011) Results from the 2010 national survey on drug use and health: summary of national findings. Substance Abuse and Mental Health Services Administration, Rockville
- World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders. World Health Organization, Geneva
Cited by
Items 101–133 of 133
Hadley, M., Halliday, A., & Stone, J. M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2287081 · Cited by 2
“Type I HPPD constitutes brief and benign reexperiencing of hallucinogenic effects that have little or no effect on everyday functioning and which, in many cases, are associated with a pleasant state (Halpern, Lerner, and Passie 2018; Lerner et al. 2002, 2014; Matefy, Hayes, and Hirsch 1978).”
Lange, B., Morgan, L., Mattox, C., Pathak, S., Liu, K., Nadar, R. M., ren, J., Jeyabalan, J. B., Moore, T., & Dhanasekaran, M. (2024) · Trends in Medical Research · doi:10.3923/tmr.2024.245.273 · Cited by 1
“Hallucinogen Persisting Perception Disorder (HPPD) is a possible effect after using psilocybin 115 .”
Psykologisk behandling av vedvarende vansker etter bruk av psykedelika
Holmøy, B., & Andersen, K. A. A. (2025) · Tidsskrift for Norsk psykologforening · doi:10.52734/qaow7353 · Cited by 1
Žuljević, M. F., & Majić, T. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_610 · Cited by 5
Berg, C. J., McCready, D. M., LoParco, C. R., Schubel, L., Romm, K. F., Thakkar, S., Williams, J., Cavazos‐Rehg, P. A., & Yang, Y. T. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2685527 · Cited by 1
The rebirth of psychedelic psychiatry
Holoyda, B. J. (2021) · Current Psychiatry · doi:10.12788/cp.0079 · Cited by 1
Fitzpatrick, C. M., Anderson, B. T., Agin-Liebes, G., & Guydish, J. R. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1983673 · Cited by 1
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Kaiserman, A., Vanderijst, L., & Kornreich, C. (2024) · Psychiatria Danubina · doi:10.24869/psyd.2024.174 · Cited by 2
“Indeed, HPPD can potentially be seen as a trauma response caused by lin-gering effects of the original experience: in a study of 19 subjects with HPPD, all remembered feeling anxious during the event that triggered the symptoms (Halpern et al. 2018).”
Reuter, J. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-15340-2.00004-5
Forstmann, M., & Sagioglou, C. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2489x
Neue und experimentelle medikamentöse Therapieverfahren
Mertens, L. J., Hart, X. M., Scharf, D., Spangemacher, M., & Gründer, G. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_11
McConnell, A., He, W., McConnell, H. W., & Sowman, P. F. (2023) · doi:10.31234/osf.io/xeg96
Laurenz, L. J., & Thomasius, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_25
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Borgwardt, S., Majić, T., Avram, M., & Herwig, U. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2264-6472
Open MDMA: An Open Source Framework and Practical Guide for the Therapeutic use of MDMAPreprint
Groeneveld, M., & Harper, T. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/aps5g
Postakute Effekte von klassischen Psychedelika
Evens, R., & Majić, T. (2024) · Nervenheilkunde · doi:10.1055/a-2305-6591
Psilocybin and other Psychedelics
Kaye, A. P., Kelmendi, B., Rivera, M. N., & Pittenger, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00178-0
Wang, V. S., & Silberstein, S. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-24705-7.00015-6
Assisted Psychedelic Psychotherapy: Rethinking the Paradigms of Psychiatric Care?
Mea, E., & Clemente, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1008154
Groeneveld, M., & Harper, T. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/aps5g_v1
Groeneveld, M., & Harper, T. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/aps5g_v3
Groeneveld, M., & Harper, T. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/aps5g_v4 · Cited by 1
Psychedelic agents for treatment-resistant depression
Gukasyan, N., & Griffiths, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00014-1
Puledda, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-86923-5_12
Wopfner, A., Beck, T., & Penzenstadler, L. E. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000954 · Cited by 1
Klepacz, J., Swędrak, R., Swojnóg, M., & Dobrakowska, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4582
Ten practical suggestions for setting up a psychedelic study
Caulfield, A., Butler, M., & Mehta, M. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261458350
“The aetiology of HPPD is complex (Butler et al., 2026; Halpern and Pope, 2003; Halpern et al., 2018; Vis et al., 2021; Zhou et al., 2025), but is best conceptualised as a functional or somatic disorder with symptoms modulated by anxiety (Butler et al., 2026).”
Ricci, V., Martinotti, G., Pettorruso, M., & Maina, G. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2689028
Indikationen, Kontraindikationen, Risiken und Nebenwirkungen
Evens, R. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00010-1
Zhang, X., Zhang, X., Zhang, H., & Wei, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188052
“…that it can induce psychological adverse reactions such as hallucinations, fear, anxiety, sleep disturbances, new-onset or exacerbated manic symptoms, and hallucinogen persisting perception disorder [95], as well as physiological adverse reactions including headache, dizziness, and nausea [96,97].”
Metadata
- Authors
- Halpern, J. H., Lerner, A. G., & Passie, T.
- Affiliations
- Harvard University (US)
- Tel Aviv University (IL)
- Goethe University Frankfurt (DE)
- Corresponding author
- Halpern, John H.
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer Berlin Heidelberg
- Published
- 2016
- Volume
- 36
- Pages
- 333-360
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W2552761136
- Cited by
- 133
- References
- 55
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 25 · 2023: 17 · 2022: 23 · 2021: 16 · 2020: 12 · 2019: 4 · 2018: 5 · 2017: 4
- FWCI
- 26.44
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- hallucinogen persisting perception disorder, perceptual distortion, dissociative symptoms, anxiety, tinnitus, psychiatric comorbidity
- MeSH terms
- Adolescent, Adult, Chronic Disease, Female, Hallucinations, Hallucinogens, Humans, Male, Perceptual Disorders, Surveys and Questionnaires, Risk Factors, Prevalence, Diagnostic and Statistical Manual of Mental Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.